SLC5A2 and hydrops fetalis: In summary, based on the findings from the meta-analysis of Gager et al. (1) and ours, SGLT2 inhibitors should be recommended in a broad population of patients with HF patients, those with diabetes or not, those with reduced eGFR or not, and those with preserved/reduced LVEF.